133 related articles for article (PubMed ID: 4039984)
21. Bioavailability and pharmacokinetics of etoposide (VP-16).
Smyth RD; Pfeffer M; Scalzo A; Comis RL
Semin Oncol; 1985 Mar; 12(1 Suppl 2):48-51. PubMed ID: 3975657
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of VP16-213 given by different administration methods.
D'Incalci M; Farina P; Sessa C; Mangioni C; Conter V; Masera G; Rocchetti M; Pisoni MB; Piazza E; Beer M; Cavalli F
Cancer Chemother Pharmacol; 1982; 7(2-3):141-5. PubMed ID: 7083454
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
24. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
[TBL] [Abstract][Full Text] [Related]
25. [Phase I clinical study of NK 171 (etoposide)].
Kimura K; Yamada K; Niitani H
Gan To Kagaku Ryoho; 1985 Apr; 12(4):851-6. PubMed ID: 2985006
[TBL] [Abstract][Full Text] [Related]
26. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
Wolff SN; Johnson DH; Hainsworth JD; Greco FA
J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
[TBL] [Abstract][Full Text] [Related]
27. [The antitumor activity of intraperitoneally- or orally-administered etoposide in animals and its administration-schedule dependency].
Okamoto K; Nishikawa K; Seki T; Shibasaki C; Uchida T; Takahashi K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2331-7. PubMed ID: 4073928
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
[TBL] [Abstract][Full Text] [Related]
29. [Complete remission obtained in advanced testicular cancer treated by etoposide (NK-171)].
Babaya K; Tsumatani K; Natsume O; Yoshie T; Kubota K; Ozono S; Hirao Y; Okajima E
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):604-7. PubMed ID: 2420282
[TBL] [Abstract][Full Text] [Related]
30. Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs.
Igwemezie LN; Kaul S; Barbhaiya RH
Pharm Res; 1995 Jan; 12(1):117-23. PubMed ID: 7724471
[TBL] [Abstract][Full Text] [Related]
31. [Anticancer effect of VP16-213 (etoposide) on three choriocarcinoma cell lines].
Matsui H; Kobayashi O; Shirotake S; Sekiya S; Takamizawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jun; 39(6):933-9. PubMed ID: 3611870
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
33. Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.
Ohune T; Fujiwara Y; Sumiyoshi H; Yamaoka N; Yamakido M
Jpn J Cancer Res; 1995 May; 86(5):490-500. PubMed ID: 7790322
[TBL] [Abstract][Full Text] [Related]
34. Uterine choriocarcinoma accompanied by an extremely high human chorionic gonadotropin level and thyrotoxicosis.
Hsieh TY; Hsu KF; Kuo PL; Huang SC
J Obstet Gynaecol Res; 2008 Apr; 34(2):274-8. PubMed ID: 18412797
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of etoposide for carcinoma of the prostate.
Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
[TBL] [Abstract][Full Text] [Related]
37. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
Aydiner A; Koyuncu H; Tas F; Topuz E; Disci R
Int J Clin Pharmacol Res; 2000; 20(1-2):21-30. PubMed ID: 11146899
[TBL] [Abstract][Full Text] [Related]
38. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
40. [Anti-tumor and adverse effect of etoposide and cisplatin on human choriocarcinoma transplanted to nude mice--a correlation between effect and tissue distribution of the drugs].
Adachi S; Yoshiya N; Misawa Y; Ishida M; Kanazawa K; Takeuchi S; Tanaka K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2031-6. PubMed ID: 3794452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
